Des Moines, Iowa-based Principal Financial Group, Inc. (PFG), is a leading global financial services provider that offers a wide range of financial products and services to individuals, corporations, and institutional clients. With a market cap of $19.7 billion, the company offers retirement solutions, life and health insurance, wellness programs, and investment and banking products. Companies worth $10 billion or more are generally described as “large-cap stocks,” and PFG perfectly fits that description ...

Core Insights - MetLife, Inc. has a market capitalization of $50.3 billion and operates in various financial services sectors, including insurance and asset management [1] - The company is categorized as a "large-cap" stock, providing a diverse range of products such as life and health insurance, pension risk transfers, and capital markets investments [2] Stock Performance - MetLife's stock has decreased by 13.9% from its 52-week high of $88.59 and has fallen 6.2% over the past three months, which is a more significant decline compared to the Financial Select Sector SPDR Fund's (XLF) 2% drop [3] - Year-to-date, MET stock is down 6.8%, underperforming XLF's 9.4% gain, and has fallen 13.5% over the past 52 weeks, while XLF has returned over 3% [4] Financial Results - In Q3 2025, MetLife reported net income of $818 million and adjusted EPS increased by 21% to $2.34, alongside strong investment income and sales momentum in key regions like Asia [5] - The company returned $875 million to shareholders and secured $12 billion in new pension risk transfer mandates, yet the stock fell by 3.4% the following day [5] Competitive Position - Rival Aflac Incorporated has outperformed MetLife, with Aflac's shares gaining 5.9% year-to-date and dropping 3.9% over the past 52 weeks [6] - Despite MetLife's underperformance, analysts maintain a moderately optimistic outlook, with a consensus rating of "Moderate Buy" and a mean price target of $93.38, indicating a potential upside of 22.4% from current levels [6]

Leadership Changes - Prudential has announced leadership changes following the departure of regional CEO John Cai for personal reasons [1] - Naveen Tahilyani will take on an expanded role covering South East Asian markets, including Malaysia, the Philippines, and Indonesia, as well as Africa and India [1][2] - Dennis Tan will now oversee Vietnam and the Laos, Cambodia, and Myanmar cluster, while Angel Ng continues as regional CEO for Greater China [2] Company Overview - Prudential provides life and health insurance and asset management services across India, ASEAN, Greater China, and Africa [3] - The company is listed on the Hong Kong and London stock exchanges, with additional listings in Singapore and New York [3] - Prudential is part of the Hang Seng Composite Index and is traded through Shenzhen-Hong Kong and Shanghai-Hong Kong Stock Connect programmes [3] Strategic Initiatives - In March 2025, Prudential plans to establish a stand-alone health insurance business through a joint venture with Vama Sundari Investments to address healthcare needs in India [4] - This initiative aligns with the Indian Government's goal of 'Insurance for All by 2047' [4]

Core Insights - Prudential Financial, Inc. (NYSE:PRU) is recognized as one of the 11 Best FTSE Dividend Stocks to buy currently [1] - Bank of America (BofA) has raised its price target for Prudential from $112 to $118 while maintaining a Neutral rating [3] - Prudential has a strong history of shareholder returns, having paid dividends for 16 consecutive years, with a current quarterly dividend of $1.35 per share and a dividend yield of 5.35% as of October 29 [4] Company Overview - Prudential Financial, Inc. is a global insurance company that provides life and health insurance, as well as asset management services [2] - The company experienced a relatively calm third quarter, with no hurricanes impacting the US, and macroeconomic uncertainties did not significantly affect earnings [3] Financial Performance - The increase in price target reflects a revision of price targets for US insurance companies within BofA's coverage [3] - The consistent dividend payments and yield indicate a stable financial performance and commitment to returning value to shareholders [4]

Core Viewpoint - Globe Life reported quarterly earnings of $4.81 per share, exceeding the Zacks Consensus Estimate of $4.54 per share, and showing an increase from $3.49 per share a year ago, representing an earnings surprise of +5.95% [1][2] Financial Performance - The company posted revenues of $1.52 billion for the quarter ended September 2025, which was slightly below the Zacks Consensus Estimate by 0.12%, and an increase from $1.46 billion year-over-year [2] - Over the last four quarters, Globe Life has surpassed consensus EPS estimates three times but has not beaten consensus revenue estimates during the same period [2] Stock Performance - Globe Life shares have increased approximately 22% since the beginning of the year, outperforming the S&P 500's gain of 14.5% [3] Future Outlook - The company's earnings outlook is crucial for investors, including current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $3.57 on revenues of $1.54 billion, and for the current fiscal year, it is $14.43 on revenues of $6.04 billion [7] Industry Context - The Insurance - Accident and Health industry, to which Globe Life belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, indicating potential challenges ahead [8]

Core Insights - Three stocks with strong momentum and buy rankings are highlighted for investors: Gold Fields Limited, Genmab, and Aegon [1][2][3]. Group 1: Gold Fields Limited (GFI) - Gold Fields Limited is one of the world's largest unhedged gold producers with operations in South Africa, Ghana, and Australia [1]. - The company has a Zacks Rank 1 (Strong Buy) and its current year earnings estimate increased by 7% over the last 60 days [1]. - Gold Fields' shares gained 76.1% over the last three months, significantly outperforming the S&P 500's gain of 7% [2]. - The company possesses a Momentum Score of A [2]. Group 2: Genmab (GMAB) - Genmab is a biotechnology company specializing in antibody therapeutics for cancer treatment [2]. - The company also has a Zacks Rank 1 and its current year earnings estimate increased by 10.1% over the last 60 days [2][3]. - Genmab's shares gained 58.2% over the last three months, again outperforming the S&P 500's gain of 7% [3]. - The company possesses a Momentum Score of A [3]. Group 3: Aegon (AEG) - Aegon is an international insurance group providing life and health insurance, as well as pension, savings, and investment products in Europe, North America, and the Caribbean [3][4]. - The company has a Zacks Rank 1 and its current year earnings estimate increased by 10.1% over the last 60 days [3][4]. - Aegon's shares gained 11.1% over the last three months, outperforming the S&P 500's gain of 7% [4]. - The company possesses a Momentum Score of A [4].

Group 1 - CNO Financial Group, Inc. declared a quarterly cash dividend of $0.17 per share on common shares [1] - The dividend is payable on September 24, 2025, to shareholders of record as of September 10, 2025 [1] Group 2 - CNO Financial Group provides life and health insurance, annuities, financial services, and workforce benefits solutions [2] - The company serves middle-income America with 3.2 million policies and total assets of $37.3 billion [2] - CNO has a workforce of 3,400 associates, 4,900 exclusive agents, and over 6,000 independent partner agents [2]

Core Viewpoint - CNO Financial Group reported a decrease in net income for the second quarter of 2025, with net income at $91.8 million or $0.91 per diluted share, down from $116.3 million or $1.06 per diluted share in the same quarter of 2024, primarily due to non-economic accounting impacts from market volatility [1][6][29] Financial Performance - Net operating income for 2Q25 was $87.5 million, or $0.87 per diluted share, compared to $114.6 million, or $1.05 per diluted share in 2Q24, reflecting a 24% decrease [1][3][29] - Total revenues for 2Q25 were $1,151.5 million, up from $1,066.2 million in 2Q24, indicating a year-over-year increase [29] - The company returned $116.7 million to shareholders during the quarter [5] Key Metrics - Book value per share was $25.92, an increase from $24.75 at the end of 2024, while book value per diluted share, excluding accumulated other comprehensive loss, was $38.05, up from $37.35 [20] - Return on equity (ROE) for the trailing four quarters was 11.9%, down from 19.9% in the previous year [22] - Operating ROE for the same period was 11.8%, compared to 11.2% in the prior year [22] Business Growth - Total new annualized premiums (NAP) increased by 17%, with life NAP up 22% and health NAP up 11% [5] - Annuity collected premiums rose by 19%, and client assets in brokerage and advisory increased by 27% [5] Investment Portfolio - As of June 30, 2025, the fair value of CNO's available-for-sale fixed maturity portfolio was $23,047 million, with net unrealized losses of $2,339.8 million [17] - The consolidated statutory risk-based capital ratio of U.S.-based insurance subsidiaries was estimated at 378% [18] Shareholder Actions - During 2Q25, the company repurchased $100 million of common stock, with an average cost of $38.09 per share [19] - Dividends paid on common stock totaled $16.7 million during the quarter [19]

Core Insights - Atlantic American Corporation reported a net income of $0.8 million, or $0.03 per diluted share, for Q1 2025, a significant improvement from a net loss of ($2.0) million, or ($0.10) per diluted share, in Q1 2024 [1][10] - The increase in net income was primarily driven by a $2.4 million, or 5.3%, rise in premium revenue, totaling $46.9 million compared to $44.6 million in the same period last year [1][9] - Operating income for Q1 2025 was $0.3 million, a turnaround from an operating loss of ($2.4) million in Q1 2024, attributed to the same factors of increased premium revenue and favorable loss experience [2][9] Financial Performance - Total revenue for Q1 2025 was $50.1 million, up from $47.0 million in Q1 2024 [9] - Insurance premiums from life and health segments increased to $28.6 million from $26.7 million, while property and casualty premiums rose to $18.3 million from $17.9 million [9] - Total benefits and expenses decreased slightly to $49.1 million from $49.5 million year-over-year [9] Management Commentary - The CEO expressed satisfaction with the quarterly results, highlighting improved profitability and growth in insurance premiums, particularly in life and health segments [3] - The company anticipates that recent rate adjustments in property and casualty operations will positively impact future results [3] - Management remains optimistic about long-term growth opportunities for the company [3] Balance Sheet Highlights - As of March 31, 2025, total cash and investments stood at $268.4 million, a slight increase from $265.7 million at the end of 2024 [10] - Total assets decreased to $388.4 million from $393.4 million [10] - Total shareholders' equity increased to $102.4 million from $99.6 million, with a book value per common share rising to $4.80 from $4.61 [10]

Group 1 - CNO Financial Group, Inc. provides life and health insurance, annuities, financial services, and workforce benefits solutions, focusing on middle-income America [1] - The company manages 3.2 million policies and has total assets amounting to $37.4 billion [1] - CNO employs 3,400 associates, 4,800 exclusive agents, and over 5,500 independent partner agents to assist customers with financial decisions [1] Group 2 - At the annual meeting, nine directors were elected to serve a one-year term [2] - The executive compensation for named executive officers was approved by a non-binding advisory vote [2] - PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for 2025 [2] - The company approved an Amended and Restated Certificate of Incorporation to include a Replacement NOL Protective Amendment [2] - An Amended and Restated Long-Term Incentive Plan was approved [2] - An Amended and Restated Employee Stock Purchase Plan was also approved [2]